SUBSCRIBE: Print / eNewsletter
Treatment with lenalidomide and rituximab improved progression-free survival, compared with placebo in patients ≥70 years old with indolent non-Hodgkin lymphoma.
First-line treatment with ibrutinib plus venetoclax provided high rates of undetectable minimal residual disease in peripheral blood and bone marrow of patients with chronic lymphocytic leukemia.
Acalabrutinib alone and in combination with obinutuzumab significantly improved progression-free survival, compared with obinutuzumab plus chlorambucil in treatment-naïve patients with chronic lymphocytic leukemia
We've noticed that you're using an ad blocker
Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.
